#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Urine is a vital biofluid in mammals and could be easily collected in a noninvasive manner .
3-1	15-20	Urine	substance	new	coref	3-3[4_0]
3-2	21-23	is	_	_	_	_
3-3	24-25	a	substance[4]	giv[4]	coref	4-9[0_4]
3-4	26-31	vital	substance[4]	giv[4]	_	_
3-5	32-40	biofluid	substance[4]	giv[4]	_	_
3-6	41-43	in	substance[4]	giv[4]	_	_
3-7	44-51	mammals	substance[4]|animal	giv[4]|new	_	_
3-8	52-55	and	_	_	_	_
3-9	56-61	could	_	_	_	_
3-10	62-64	be	_	_	_	_
3-11	65-71	easily	_	_	_	_
3-12	72-81	collected	_	_	_	_
3-13	82-84	in	_	_	_	_
3-14	85-86	a	abstract[6]	new[6]	_	_
3-15	87-98	noninvasive	abstract[6]	new[6]	_	_
3-16	99-105	manner	abstract[6]	new[6]	_	_
3-17	106-107	.	_	_	_	_

#Text=Moreover , the metabolites components and concentrations in urine are good indicators of metabolic fluctuations .
4-1	108-116	Moreover	_	_	_	_
4-2	117-118	,	_	_	_	_
4-3	119-122	the	substance[8]	new[8]	_	_
4-4	123-134	metabolites	substance|substance[8]	new|new[8]	coref	22-1
4-5	135-145	components	substance[8]	new[8]	_	_
4-6	146-149	and	_	_	_	_
4-7	150-164	concentrations	abstract[9]	new[9]	coref	4-11[11_9]
4-8	165-167	in	abstract[9]	new[9]	_	_
4-9	168-173	urine	abstract[9]|substance	new[9]|giv	coref	7-15
4-10	174-177	are	_	_	_	_
4-11	178-182	good	abstract[11]	giv[11]	_	_
4-12	183-193	indicators	abstract[11]	giv[11]	_	_
4-13	194-196	of	abstract[11]	giv[11]	_	_
4-14	197-206	metabolic	abstract[11]|quantity|abstract[13]	giv[11]|new|new[13]	coref|coref	5-15|5-15
4-15	207-219	fluctuations	abstract[11]|abstract[13]	giv[11]|new[13]	_	_
4-16	220-221	.	_	_	_	_

#Text=Comparison of metabolite profiles between the treatment group and the control group could obtain metabolic changes and reveal adverse effects mechanism of stressor .
5-1	222-232	Comparison	abstract[14]	new[14]	_	_
5-2	233-235	of	abstract[14]	new[14]	_	_
5-3	236-246	metabolite	abstract[14]|substance|object[16]	new[14]|new|new[16]	_	_
5-4	247-255	profiles	abstract[14]|object[16]	new[14]|new[16]	_	_
5-5	256-263	between	abstract[14]|object[16]	new[14]|new[16]	_	_
5-6	264-267	the	abstract[14]|object[16]|place[18]	new[14]|new[16]|new[18]	_	_
5-7	268-277	treatment	abstract[14]|object[16]|abstract|place[18]	new[14]|new[16]|new|new[18]	coref	13-11
5-8	278-283	group	abstract[14]|object[16]|place[18]	new[14]|new[16]|new[18]	_	_
5-9	284-287	and	abstract[14]|object[16]	new[14]|new[16]	_	_
5-10	288-291	the	abstract[14]|object[16]|place[19]	new[14]|new[16]|new[19]	coref	13-7[84_19]
5-11	292-299	control	abstract[14]|object[16]|place[19]	new[14]|new[16]|new[19]	_	_
5-12	300-305	group	abstract[14]|object[16]|place[19]	new[14]|new[16]|new[19]	_	_
5-13	306-311	could	_	_	_	_
5-14	312-318	obtain	_	_	_	_
5-15	319-328	metabolic	person|abstract[21]	giv|new[21]	coref|coref|coref|coref	6-15|7-11[39_21]|6-15|7-11[39_21]
5-16	329-336	changes	abstract[21]	new[21]	_	_
5-17	337-340	and	_	_	_	_
5-18	341-347	reveal	_	_	_	_
5-19	348-355	adverse	abstract[23]	new[23]	_	_
5-20	356-363	effects	abstract|abstract[23]	new|new[23]	_	_
5-21	364-373	mechanism	abstract[23]	new[23]	_	_
5-22	374-376	of	abstract[23]	new[23]	_	_
5-23	377-385	stressor	abstract[23]|abstract	new[23]|new	_	_
5-24	386-387	.	_	_	_	_

#Text=In this study , 1H-NMR and UPLC-MS/MS based metabolomics were employed to investigate the metabolic perturbations after rac -metalaxyl and metalaxyl-M exposure .
6-1	388-390	In	_	_	_	_
6-2	391-395	this	abstract[25]	new[25]	_	_
6-3	396-401	study	abstract[25]	new[25]	_	_
6-4	402-403	,	_	_	_	_
6-5	404-410	1H-NMR	person	new	_	_
6-6	411-414	and	_	_	_	_
6-7	415-425	UPLC-MS/MS	person	new	_	_
6-8	426-431	based	_	_	_	_
6-9	432-444	metabolomics	abstract	new	_	_
6-10	445-449	were	_	_	_	_
6-11	450-458	employed	_	_	_	_
6-12	459-461	to	_	_	_	_
6-13	462-473	investigate	_	_	_	_
6-14	474-477	the	abstract[30]	new[30]	_	_
6-15	478-487	metabolic	person|abstract[30]	giv|new[30]	coref	7-12
6-16	488-501	perturbations	abstract[30]	new[30]	_	_
6-17	502-507	after	_	_	_	_
6-18	508-511	rac	substance|abstract[32]	new|new[32]	coref|coref|coref|coref	7-6|14-5[0_32]|7-6|14-5[0_32]
6-19	512-522	-metalaxyl	abstract[32]	new[32]	_	_
6-20	523-526	and	abstract[32]	new[32]	_	_
6-21	527-538	metalaxyl-M	abstract[32]	new[32]	_	_
6-22	539-547	exposure	abstract[32]	new[32]	_	_
6-23	548-549	.	_	_	_	_

#Text=The results showed that both rac -metalaxyl and metalaxyl-M induced systematic metabolic changes in urine and serum .
7-1	550-553	The	abstract[33]	new[33]	coref	16-1[106_33]
7-2	554-561	results	abstract[33]	new[33]	_	_
7-3	562-568	showed	_	_	_	_
7-4	569-573	that	_	_	_	_
7-5	574-578	both	abstract[35]|abstract[36]	new[35]|new[36]	coref|coref|coref|coref	15-5[99_35]|15-5[100_36]|15-5[99_35]|15-5[100_36]
7-6	579-582	rac	substance|abstract[35]|abstract[36]	giv|new[35]|new[36]	coref	14-22
7-7	583-593	-metalaxyl	abstract[35]|abstract[36]	new[35]|new[36]	_	_
7-8	594-597	and	abstract[36]	new[36]	_	_
7-9	598-609	metalaxyl-M	abstract[36]|substance	new[36]|new	coref	15-8
7-10	610-617	induced	_	_	_	_
7-11	618-628	systematic	abstract[39]	giv[39]	coref	9-8[46_39]
7-12	629-638	metabolic	person|abstract[39]	giv|giv[39]	_	_
7-13	639-646	changes	abstract[39]	giv[39]	_	_
7-14	647-649	in	abstract[39]	giv[39]	_	_
7-15	650-655	urine	abstract[39]|substance	giv[39]|giv	coref	22-10[137_0]
7-16	656-659	and	abstract[39]	giv[39]	_	_
7-17	660-665	serum	abstract[39]|substance	giv[39]|new	_	_
7-18	666-667	.	_	_	_	_

#Text=Rac
8-1	668-671	Rac	abstract	new	_	_

#Text=-metalaxyl and metalaxyl-M induced liver damages and metabolic pathway changes including glycine , serine , and threonine metabolism , citrate cycle ( TCA cycle ) , pyruvate metabolism , glycolysis or gluconeogenesis , glycerophospholipid metabolism , and glyoxylate and dicarboxylate metabolism .
9-1	672-682	-metalaxyl	abstract[44]	new[44]	coref	19-1[126_44]
9-2	683-686	and	abstract[44]	new[44]	_	_
9-3	687-698	metalaxyl-M	abstract[44]	new[44]	_	_
9-4	699-706	induced	abstract[44]	new[44]	_	_
9-5	707-712	liver	object|abstract[44]	new|new[44]	coref	12-5
9-6	713-720	damages	abstract[44]	new[44]	_	_
9-7	721-724	and	_	_	_	_
9-8	725-734	metabolic	abstract[46]	giv[46]	coref	12-1[78_46]
9-9	735-742	pathway	place|abstract[46]	new|giv[46]	_	_
9-10	743-750	changes	abstract[46]	giv[46]	_	_
9-11	751-760	including	abstract[46]	giv[46]	_	_
9-12	761-768	glycine	abstract[46]|substance	giv[46]|new	_	_
9-13	769-770	,	abstract[46]	giv[46]	_	_
9-14	771-777	serine	abstract[46]|substance	giv[46]|new	_	_
9-15	778-779	,	abstract[46]	giv[46]	_	_
9-16	780-783	and	abstract[46]	giv[46]	_	_
9-17	784-793	threonine	abstract[46]|object|abstract[50]	giv[46]|new|new[50]	coref|coref	9-27[56_50]|9-27[56_50]
9-18	794-804	metabolism	abstract[46]|abstract[50]	giv[46]|new[50]	_	_
9-19	805-806	,	abstract[46]	giv[46]	_	_
9-20	807-814	citrate	abstract[46]|person|abstract[52]	giv[46]|new|new[52]	appos|coref|appos|coref	9-23[54_52]|22-20|9-23[54_52]|22-20
9-21	815-820	cycle	abstract[46]|abstract[52]	giv[46]|new[52]	_	_
9-22	821-822	(	abstract[46]	giv[46]	_	_
9-23	823-826	TCA	abstract[46]|abstract|abstract[54]	giv[46]|new|giv[54]	coref|coref|coref|coref	23-12|23-11[153_54]|23-12|23-11[153_54]
9-24	827-832	cycle	abstract[46]|abstract[54]	giv[46]|giv[54]	_	_
9-25	833-834	)	abstract[46]	giv[46]	_	_
9-26	835-836	,	abstract[46]	giv[46]	_	_
9-27	837-845	pyruvate	abstract[46]|object|abstract[56]|abstract[57]	giv[46]|new|giv[56]|new[57]	coref|coref|coref|coref|coref|coref|coref|coref|coref	9-34[61_56]|18-10[120_57]|22-28|9-34[61_56]|18-10[120_57]|22-28|9-34[61_56]|18-10[120_57]|22-28
9-28	846-856	metabolism	abstract[46]|abstract[56]|abstract[57]	giv[46]|giv[56]|new[57]	_	_
9-29	857-858	,	abstract[46]|abstract[57]	giv[46]|new[57]	_	_
9-30	859-869	glycolysis	abstract[46]|abstract[57]|substance	giv[46]|new[57]|new	coref	23-19
9-31	870-872	or	abstract[46]	giv[46]	_	_
9-32	873-888	gluconeogenesis	abstract[46]|substance	giv[46]|new	coref	23-21
9-33	889-890	,	abstract[46]	giv[46]	_	_
9-34	891-910	glycerophospholipid	abstract[46]|object|abstract[61]	giv[46]|new|giv[61]	coref|coref	9-40[64_61]|9-40[64_61]
9-35	911-921	metabolism	abstract[46]|abstract[61]	giv[46]|giv[61]	_	_
9-36	922-923	,	abstract[46]	giv[46]	_	_
9-37	924-927	and	abstract[46]	giv[46]	_	_
9-38	928-938	glyoxylate	abstract[46]|substance	giv[46]|new	_	_
9-39	939-942	and	abstract[46]	giv[46]	_	_
9-40	943-956	dicarboxylate	abstract[46]|object|abstract[64]	giv[46]|new|giv[64]	coref|coref	10-7[67_64]|10-7[67_64]
9-41	957-967	metabolism	abstract[46]|abstract[64]	giv[46]|giv[64]	_	_
9-42	968-969	.	_	_	_	_

#Text=These pathways are highly related to energy metabolism , lipid metabolism , amino acids metabolism , microbial metabolism , and tryptophan metabolism .
10-1	970-975	These	place[65]	new[65]	coref	23-7[151_65]
10-2	976-984	pathways	place[65]	new[65]	_	_
10-3	985-988	are	_	_	_	_
10-4	989-995	highly	_	_	_	_
10-5	996-1003	related	_	_	_	_
10-6	1004-1006	to	_	_	_	_
10-7	1007-1013	energy	substance|abstract[67]	new|giv[67]	coref|coref|coref|coref	10-10[69_67]|21-1|10-10[69_67]|21-1
10-8	1014-1024	metabolism	abstract[67]	giv[67]	_	_
10-9	1025-1026	,	_	_	_	_
10-10	1027-1032	lipid	object|abstract[69]	new|giv[69]	coref|coref	10-13[71_69]|10-13[71_69]
10-11	1033-1043	metabolism	abstract[69]	giv[69]	_	_
10-12	1044-1045	,	_	_	_	_
10-13	1046-1051	amino	abstract[71]	giv[71]	coref	10-17[72_71]
10-14	1052-1057	acids	object|abstract[71]	new|giv[71]	_	_
10-15	1058-1068	metabolism	abstract[71]	giv[71]	_	_
10-16	1069-1070	,	_	_	_	_
10-17	1071-1080	microbial	abstract[72]	giv[72]	coref	10-21[74_72]
10-18	1081-1091	metabolism	abstract[72]	giv[72]	_	_
10-19	1092-1093	,	_	_	_	_
10-20	1094-1097	and	_	_	_	_
10-21	1098-1108	tryptophan	object|abstract[74]	new|giv[74]	coref|coref	18-10[0_74]|18-10[0_74]
10-22	1109-1119	metabolism	abstract[74]	giv[74]	_	_
10-23	1120-1121	.	_	_	_	_

#Text=3.1 .
11-1	1122-1125	3.1	abstract	new	_	_
11-2	1126-1127	.	_	_	_	_

#Text=Body Weight Changes and Liver Damage
12-1	1128-1132	Body	object|person[77]|abstract[78]	new|new[77]|giv[78]	coref|coref|coref|coref|coref|coref	14-7[88_78]|14-11|14-7[88_78]|14-11|14-7[88_78]|14-11
12-2	1133-1139	Weight	person[77]|abstract[78]	new[77]|giv[78]	_	_
12-3	1140-1147	Changes	person[77]|abstract[78]	new[77]|giv[78]	_	_
12-4	1148-1151	and	abstract[78]	giv[78]	_	_
12-5	1152-1157	Liver	abstract[78]|object|abstract[80]	giv[78]|giv|new[80]	coref|coref|coref|coref	16-10|17-5[114_80]|16-10|17-5[114_80]
12-6	1158-1164	Damage	abstract[78]|abstract[80]	giv[78]|new[80]	_	_

#Text=Only one mouse was dead in the 60 mg/kg metalaxyl-M treatment group during the whole experiment .
13-1	1165-1169	Only	animal[81]	new[81]	_	_
13-2	1170-1173	one	animal[81]	new[81]	_	_
13-3	1174-1179	mouse	animal[81]	new[81]	_	_
13-4	1180-1183	was	_	_	_	_
13-5	1184-1188	dead	_	_	_	_
13-6	1189-1191	in	_	_	_	_
13-7	1192-1195	the	place[84]	giv[84]	_	_
13-8	1196-1198	60	quantity[82]|place[84]	new[82]|giv[84]	_	_
13-9	1199-1204	mg/kg	quantity[82]|place[84]	new[82]|giv[84]	_	_
13-10	1205-1216	metalaxyl-M	place[84]	giv[84]	_	_
13-11	1217-1226	treatment	abstract|place[84]	giv|giv[84]	coref	14-19
13-12	1227-1232	group	place[84]	giv[84]	_	_
13-13	1233-1239	during	place[84]	giv[84]	_	_
13-14	1240-1243	the	place[84]|event[85]	giv[84]|new[85]	_	_
13-15	1244-1249	whole	place[84]|event[85]	giv[84]|new[85]	_	_
13-16	1250-1260	experiment	place[84]|event[85]	giv[84]|new[85]	_	_
13-17	1261-1262	.	_	_	_	_

#Text=After four weeks of exposure , no significant changes in body weight were observed between the control and treatment groups after rac -metalaxyl and metalaxyl-M exposure .
14-1	1263-1268	After	_	_	_	_
14-2	1269-1273	four	time[86]	new[86]	_	_
14-3	1274-1279	weeks	time[86]	new[86]	_	_
14-4	1280-1282	of	time[86]	new[86]	_	_
14-5	1283-1291	exposure	time[86]|abstract	new[86]|giv	coref	14-22[95_0]
14-6	1292-1293	,	_	_	_	_
14-7	1294-1296	no	abstract[88]	giv[88]	_	_
14-8	1297-1308	significant	abstract[88]	giv[88]	_	_
14-9	1309-1316	changes	abstract[88]	giv[88]	_	_
14-10	1317-1319	in	abstract[88]	giv[88]	_	_
14-11	1320-1324	body	abstract[88]|object|abstract[90]	giv[88]|giv|new[90]	_	_
14-12	1325-1331	weight	abstract[88]|abstract[90]	giv[88]|new[90]	_	_
14-13	1332-1336	were	_	_	_	_
14-14	1337-1345	observed	_	_	_	_
14-15	1346-1353	between	_	_	_	_
14-16	1354-1357	the	abstract[91]	new[91]	_	_
14-17	1358-1365	control	abstract[91]	new[91]	_	_
14-18	1366-1369	and	_	_	_	_
14-19	1370-1379	treatment	event|person[93]	giv|new[93]	_	_
14-20	1380-1386	groups	person[93]	new[93]	_	_
14-21	1387-1392	after	_	_	_	_
14-22	1393-1396	rac	substance|abstract[95]	giv|giv[95]	coref|coref|coref|coref	15-5|16-4[108_95]|15-5|16-4[108_95]
14-23	1397-1407	-metalaxyl	abstract[95]	giv[95]	_	_
14-24	1408-1411	and	abstract[95]	giv[95]	_	_
14-25	1412-1423	metalaxyl-M	abstract[95]	giv[95]	_	_
14-26	1424-1432	exposure	abstract[95]	giv[95]	_	_
14-27	1433-1434	.	_	_	_	_

#Text=Histopathology examination showed that rac -metalaxyl and metalaxyl-M can both induce hepatocellular inflammation , necrosis , and vacuolation in mice .
15-1	1435-1449	Histopathology	place|abstract[97]	new|new[97]	_	_
15-2	1450-1461	examination	abstract[97]	new[97]	_	_
15-3	1462-1468	showed	_	_	_	_
15-4	1469-1473	that	_	_	_	_
15-5	1474-1477	rac	substance|abstract[99]|abstract[100]	giv|giv[99]|giv[100]	coref|coref|coref|coref|coref|coref|coref|coref|coref	16-4|22-13[139_99]|22-13[140_100]|16-4|22-13[139_99]|22-13[140_100]|16-4|22-13[139_99]|22-13[140_100]
15-6	1478-1488	-metalaxyl	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
15-7	1489-1492	and	abstract[100]	giv[100]	_	_
15-8	1493-1504	metalaxyl-M	abstract[100]|substance	giv[100]|giv	coref	17-3
15-9	1505-1508	can	_	_	_	_
15-10	1509-1513	both	_	_	_	_
15-11	1514-1520	induce	_	_	_	_
15-12	1521-1535	hepatocellular	abstract[102]	new[102]	_	_
15-13	1536-1548	inflammation	abstract[102]	new[102]	_	_
15-14	1549-1550	,	_	_	_	_
15-15	1551-1559	necrosis	event	new	_	_
15-16	1560-1561	,	_	_	_	_
15-17	1562-1565	and	_	_	_	_
15-18	1566-1577	vacuolation	abstract[104]	new[104]	_	_
15-19	1578-1580	in	abstract[104]	new[104]	_	_
15-20	1581-1585	mice	abstract[104]|animal	new[104]|new	coref	16-13
15-21	1586-1587	.	_	_	_	_

#Text=Such results suggested rac -metalaxyl and metalaxyl-M exposure caused liver dysfunction in mice .
16-1	1588-1592	Such	abstract[106]	giv[106]	coref	30-5[208_106]
16-2	1593-1600	results	abstract[106]	giv[106]	_	_
16-3	1601-1610	suggested	_	_	_	_
16-4	1611-1614	rac	substance|abstract[108]	giv|giv[108]	coref|coref|coref|coref	17-9|22-16[142_108]|17-9|22-16[142_108]
16-5	1615-1625	-metalaxyl	abstract[108]	giv[108]	_	_
16-6	1626-1629	and	abstract[108]	giv[108]	_	_
16-7	1630-1641	metalaxyl-M	abstract[108]	giv[108]	_	_
16-8	1642-1650	exposure	abstract[108]	giv[108]	_	_
16-9	1651-1657	caused	_	_	_	_
16-10	1658-1663	liver	object|abstract[110]	giv|new[110]	coref|coref	17-6|17-6
16-11	1664-1675	dysfunction	abstract[110]	new[110]	_	_
16-12	1676-1678	in	_	_	_	_
16-13	1679-1683	mice	animal	giv	coref	19-12
16-14	1684-1685	.	_	_	_	_

#Text=Moreover , metalaxyl-M induced greater liver damage than rac -metalaxyl at the same dosage .
17-1	1686-1694	Moreover	_	_	_	_
17-2	1695-1696	,	_	_	_	_
17-3	1697-1708	metalaxyl-M	substance	giv	coref	22-16
17-4	1709-1716	induced	_	_	_	_
17-5	1717-1724	greater	abstract[114]	giv[114]	_	_
17-6	1725-1730	liver	object|abstract[114]	giv|giv[114]	coref	18-1[117_0]
17-7	1731-1737	damage	abstract[114]	giv[114]	_	_
17-8	1738-1742	than	abstract[114]	giv[114]	_	_
17-9	1743-1746	rac	abstract[114]|substance	giv[114]|giv	coref	22-13
17-10	1747-1757	-metalaxyl	abstract[116]	new[116]	_	_
17-11	1758-1760	at	abstract[116]	new[116]	_	_
17-12	1761-1764	the	abstract[116]	new[116]	_	_
17-13	1765-1769	same	abstract[116]	new[116]	_	_
17-14	1770-1776	dosage	abstract[116]	new[116]	_	_
17-15	1777-1778	.	_	_	_	_

#Text=The liver is a fundamental and essential organ for metabolism and detoxification of xenobiotics with abundant cytochrome P450 enzymes .
18-1	1779-1782	The	object[117]	giv[117]	coref	18-4[118_117]
18-2	1783-1788	liver	object[117]	giv[117]	_	_
18-3	1789-1791	is	_	_	_	_
18-4	1792-1793	a	object[118]	giv[118]	coref	19-4[127_118]
18-5	1794-1805	fundamental	object[118]	giv[118]	_	_
18-6	1806-1809	and	object[118]	giv[118]	_	_
18-7	1810-1819	essential	object[118]	giv[118]	_	_
18-8	1820-1825	organ	object[118]	giv[118]	_	_
18-9	1826-1829	for	object[118]	giv[118]	_	_
18-10	1830-1840	metabolism	object[118]|abstract|abstract[120]	giv[118]|giv|giv[120]	coref|coref	21-1[132_0]|21-1[132_0]
18-11	1841-1844	and	object[118]|abstract[120]	giv[118]|giv[120]	_	_
18-12	1845-1859	detoxification	object[118]|abstract[120]|abstract[121]	giv[118]|giv[120]|new[121]	_	_
18-13	1860-1862	of	object[118]|abstract[120]|abstract[121]	giv[118]|giv[120]|new[121]	_	_
18-14	1863-1874	xenobiotics	object[118]|abstract[120]|abstract[121]|substance[122]	giv[118]|giv[120]|new[121]|new[122]	_	_
18-15	1875-1879	with	object[118]|abstract[120]|abstract[121]|substance[122]	giv[118]|giv[120]|new[121]|new[122]	_	_
18-16	1880-1888	abundant	object[118]|abstract[120]|abstract[121]|substance[122]|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new[125]	coref	25-28[176_125]
18-17	1889-1899	cytochrome	object[118]|abstract[120]|abstract[121]|substance[122]|abstract|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new|new[125]	_	_
18-18	1900-1904	P450	object[118]|abstract[120]|abstract[121]|substance[122]|abstract|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new|new[125]	_	_
18-19	1905-1912	enzymes	object[118]|abstract[120]|abstract[121]|substance[122]|abstract[125]	giv[118]|giv[120]|new[121]|new[122]|new[125]	_	_
18-20	1913-1914	.	_	_	_	_

#Text=The damages of the liver may greatly affect the detoxification of mice .
19-1	1915-1918	The	abstract[126]	giv[126]	_	_
19-2	1919-1926	damages	abstract[126]	giv[126]	_	_
19-3	1927-1929	of	abstract[126]	giv[126]	_	_
19-4	1930-1933	the	abstract[126]|object[127]	giv[126]|giv[127]	coref	24-18[0_127]
19-5	1934-1939	liver	abstract[126]|object[127]	giv[126]|giv[127]	_	_
19-6	1940-1943	may	_	_	_	_
19-7	1944-1951	greatly	_	_	_	_
19-8	1952-1958	affect	_	_	_	_
19-9	1959-1962	the	abstract[128]	new[128]	_	_
19-10	1963-1977	detoxification	abstract[128]	new[128]	_	_
19-11	1978-1980	of	abstract[128]	new[128]	_	_
19-12	1981-1985	mice	abstract[128]|animal	new[128]|giv	coref	22-10
19-13	1986-1987	.	_	_	_	_

#Text=3.2 .
20-1	1988-1991	3.2	abstract	new	_	_
20-2	1992-1993	.	_	_	_	_

#Text=Energy Metabolism
21-1	1994-2000	Energy	abstract|abstract[132]	giv|giv[132]	coref|coref|coref|coref	22-4|22-4[135_132]|22-4|22-4[135_132]
21-2	2001-2011	Metabolism	abstract[132]	giv[132]	_	_

#Text=Metabolites involved in energy metabolism were significant changed in mice urine after rac -metalaxyl and metalaxyl-M exposure , including citrate , succinate , lactate , alanine , pyruvate , and acetate .
22-1	2012-2023	Metabolites	substance	giv	coref	23-1[149_0]
22-2	2024-2032	involved	_	_	_	_
22-3	2033-2035	in	_	_	_	_
22-4	2036-2042	energy	substance|abstract[135]	giv|giv[135]	coref|coref|coref|coref	23-7|23-15[155_135]|23-7|23-15[155_135]
22-5	2043-2053	metabolism	abstract[135]	giv[135]	_	_
22-6	2054-2058	were	_	_	_	_
22-7	2059-2070	significant	_	_	_	_
22-8	2071-2078	changed	_	_	_	_
22-9	2079-2081	in	_	_	_	_
22-10	2082-2086	mice	animal|substance[137]	giv|giv[137]	coref|coref|coref|coref	25-16[171_137]|25-19[172_0]|25-16[171_137]|25-19[172_0]
22-11	2087-2092	urine	substance[137]	giv[137]	_	_
22-12	2093-2098	after	substance[137]	giv[137]	_	_
22-13	2099-2102	rac	substance[137]|substance|abstract[139]|abstract[140]	giv[137]|giv|giv[139]|giv[140]	coref|coref|coref|coref|coref|coref|coref|coref|coref	30-16|30-16[214_139]|30-16[215_140]|30-16|30-16[214_139]|30-16[215_140]|30-16|30-16[214_139]|30-16[215_140]
22-14	2103-2113	-metalaxyl	substance[137]|abstract[139]|abstract[140]	giv[137]|giv[139]|giv[140]	_	_
22-15	2114-2117	and	substance[137]|abstract[140]	giv[137]|giv[140]	_	_
22-16	2118-2129	metalaxyl-M	substance[137]|abstract[140]|substance|abstract[142]	giv[137]|giv[140]|giv|giv[142]	coref|coref|coref|coref	25-23|30-19[216_142]|25-23|30-19[216_142]
22-17	2130-2138	exposure	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-18	2139-2140	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-19	2141-2150	including	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-20	2151-2158	citrate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|giv	coref	24-1
22-21	2159-2160	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-22	2161-2170	succinate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	coref	24-3
22-23	2171-2172	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-24	2173-2180	lactate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	coref	26-13
22-25	2181-2182	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-26	2183-2190	alanine	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	coref	26-15
22-27	2191-2192	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-28	2193-2201	pyruvate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|giv	coref	23-15
22-29	2202-2203	,	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-30	2204-2207	and	substance[137]|abstract[140]|abstract[142]	giv[137]|giv[140]|giv[142]	_	_
22-31	2208-2215	acetate	substance[137]|abstract[140]|abstract[142]|substance	giv[137]|giv[140]|giv[142]|new	_	_
22-32	2216-2217	.	_	_	_	_

#Text=These metabolites are highly related to energy pathways , including the TCA cycle , pyruvate metabolism , and glycolysis or gluconeogenesis .
23-1	2218-2223	These	substance[149]	giv[149]	coref	39-1[256_149]
23-2	2224-2235	metabolites	substance[149]	giv[149]	_	_
23-3	2236-2239	are	_	_	_	_
23-4	2240-2246	highly	_	_	_	_
23-5	2247-2254	related	_	_	_	_
23-6	2255-2257	to	_	_	_	_
23-7	2258-2264	energy	abstract|place[151]	giv|giv[151]	coref|coref	25-41|25-41
23-8	2265-2273	pathways	place[151]	giv[151]	_	_
23-9	2274-2275	,	place[151]	giv[151]	_	_
23-10	2276-2285	including	place[151]	giv[151]	_	_
23-11	2286-2289	the	place[151]|abstract[153]	giv[151]|giv[153]	coref	24-9[163_153]
23-12	2290-2293	TCA	place[151]|abstract|abstract[153]	giv[151]|giv|giv[153]	coref	24-10
23-13	2294-2299	cycle	place[151]|abstract[153]	giv[151]|giv[153]	_	_
23-14	2300-2301	,	place[151]	giv[151]	_	_
23-15	2302-2310	pyruvate	place[151]|object|abstract[155]	giv[151]|giv|giv[155]	coref|coref|coref|coref	25-41[181_155]|26-8|25-41[181_155]|26-8
23-16	2311-2321	metabolism	place[151]|abstract[155]	giv[151]|giv[155]	_	_
23-17	2322-2323	,	place[151]	giv[151]	_	_
23-18	2324-2327	and	place[151]	giv[151]	_	_
23-19	2328-2338	glycolysis	place[151]|substance	giv[151]|giv	_	_
23-20	2339-2341	or	place[151]	giv[151]	_	_
23-21	2342-2357	gluconeogenesis	place[151]|substance	giv[151]|giv	_	_
23-22	2358-2359	.	_	_	_	_

#Text=Citrate and succinate are the main intermediates in the TCA cycle , which is mainly appeared in liver mitochondria .
24-1	2360-2367	Citrate	substance|substance[159]	giv|new[159]	coref|coref|coref|coref	25-12|25-12[169_159]|25-12|25-12[169_159]
24-2	2368-2371	and	substance[159]	new[159]	_	_
24-3	2372-2381	succinate	substance[159]|substance	new[159]|giv	coref	24-5[161_0]
24-4	2382-2385	are	_	_	_	_
24-5	2386-2389	the	substance[161]	giv[161]	coref	25-14[0_161]
24-6	2390-2394	main	substance[161]	giv[161]	_	_
24-7	2395-2408	intermediates	substance[161]	giv[161]	_	_
24-8	2409-2411	in	substance[161]	giv[161]	_	_
24-9	2412-2415	the	substance[161]|abstract[163]	giv[161]|giv[163]	coref	25-32[178_163]
24-10	2416-2419	TCA	substance[161]|abstract|abstract[163]	giv[161]|giv|giv[163]	coref	25-33
24-11	2420-2425	cycle	substance[161]|abstract[163]	giv[161]|giv[163]	_	_
24-12	2426-2427	,	_	_	_	_
24-13	2428-2433	which	_	_	_	_
24-14	2434-2436	is	_	_	_	_
24-15	2437-2443	mainly	_	_	_	_
24-16	2444-2452	appeared	_	_	_	_
24-17	2453-2455	in	_	_	_	_
24-18	2456-2461	liver	object|place[165]	giv|new[165]	coref|coref	25-28[0_165]|25-28[0_165]
24-19	2462-2474	mitochondria	place[165]	new[165]	_	_
24-20	2475-2476	.	_	_	_	_

#Text=Although other factors cannot be excluded , the increased levels of citrate and succinate in the urine of metalaxyl-M-treated mice indicated that metalaxyl-M affected the activity of mitochondria enzymes involved in the TCA cycle , resulting in the enhancement of energy metabolism in treated mice .
25-1	2477-2485	Although	_	_	_	_
25-2	2486-2491	other	abstract[166]	new[166]	_	_
25-3	2492-2499	factors	abstract[166]	new[166]	_	_
25-4	2500-2506	cannot	_	_	_	_
25-5	2507-2509	be	_	_	_	_
25-6	2510-2518	excluded	_	_	_	_
25-7	2519-2520	,	_	_	_	_
25-8	2521-2524	the	abstract[167]	new[167]	_	_
25-9	2525-2534	increased	abstract[167]	new[167]	_	_
25-10	2535-2541	levels	abstract[167]	new[167]	_	_
25-11	2542-2544	of	abstract[167]	new[167]	_	_
25-12	2545-2552	citrate	abstract[167]|substance|substance[169]	new[167]|giv|giv[169]	coref|coref	27-21|27-21
25-13	2553-2556	and	abstract[167]|substance[169]	new[167]|giv[169]	_	_
25-14	2557-2566	succinate	abstract[167]|substance[169]|substance	new[167]|giv[169]|giv	_	_
25-15	2567-2569	in	abstract[167]	new[167]	_	_
25-16	2570-2573	the	abstract[167]|substance[171]	new[167]|giv[171]	coref	42-5[0_171]
25-17	2574-2579	urine	abstract[167]|substance[171]	new[167]|giv[171]	_	_
25-18	2580-2582	of	abstract[167]|substance[171]	new[167]|giv[171]	_	_
25-19	2583-2602	metalaxyl-M-treated	abstract[167]|substance[171]|animal[172]	new[167]|giv[171]|giv[172]	coref	25-44[182_172]
25-20	2603-2607	mice	abstract[167]|substance[171]|animal[172]	new[167]|giv[171]|giv[172]	_	_
25-21	2608-2617	indicated	_	_	_	_
25-22	2618-2622	that	_	_	_	_
25-23	2623-2634	metalaxyl-M	substance	giv	coref	34-5
25-24	2635-2643	affected	_	_	_	_
25-25	2644-2647	the	abstract[174]	new[174]	_	_
25-26	2648-2656	activity	abstract[174]	new[174]	_	_
25-27	2657-2659	of	abstract[174]	new[174]	_	_
25-28	2660-2672	mitochondria	abstract[174]|place|abstract[176]	new[174]|giv|giv[176]	_	_
25-29	2673-2680	enzymes	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
25-30	2681-2689	involved	_	_	_	_
25-31	2690-2692	in	_	_	_	_
25-32	2693-2696	the	abstract[178]	giv[178]	_	_
25-33	2697-2700	TCA	abstract|abstract[178]	giv|giv[178]	_	_
25-34	2701-2706	cycle	abstract[178]	giv[178]	_	_
25-35	2707-2708	,	_	_	_	_
25-36	2709-2718	resulting	_	_	_	_
25-37	2719-2721	in	_	_	_	_
25-38	2722-2725	the	abstract[179]	new[179]	_	_
25-39	2726-2737	enhancement	abstract[179]	new[179]	_	_
25-40	2738-2740	of	abstract[179]	new[179]	_	_
25-41	2741-2747	energy	abstract[179]|substance|abstract[181]	new[179]|giv|giv[181]	coref|coref|coref|coref	26-20[190_181]|29-18|26-20[190_181]|29-18
25-42	2748-2758	metabolism	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
25-43	2759-2761	in	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
25-44	2762-2769	treated	abstract[179]|abstract[181]|animal[182]	new[179]|giv[181]|giv[182]	coref	30-14[0_182]
25-45	2770-2774	mice	abstract[179]|abstract[181]|animal[182]	new[179]|giv[181]|giv[182]	_	_
25-46	2775-2776	.	_	_	_	_

#Text=In addition , the decreased level of pyruvate and increased levels of lactate and alanine were highly related to pyruvate metabolism .
26-1	2777-2779	In	_	_	_	_
26-2	2780-2788	addition	_	_	_	_
26-3	2789-2790	,	_	_	_	_
26-4	2791-2794	the	abstract[183]	new[183]	_	_
26-5	2795-2804	decreased	abstract[183]	new[183]	_	_
26-6	2805-2810	level	abstract[183]	new[183]	_	_
26-7	2811-2813	of	abstract[183]	new[183]	_	_
26-8	2814-2822	pyruvate	abstract[183]|substance	new[183]|giv	coref	26-20
26-9	2823-2826	and	_	_	_	_
26-10	2827-2836	increased	_	_	_	_
26-11	2837-2843	levels	abstract[185]	new[185]	_	_
26-12	2844-2846	of	abstract[185]	new[185]	_	_
26-13	2847-2854	lactate	abstract[185]|substance|substance[187]	new[185]|giv|new[187]	coref|coref|coref|coref	28-1|28-1[198_187]|28-1|28-1[198_187]
26-14	2855-2858	and	abstract[185]|substance[187]	new[185]|new[187]	_	_
26-15	2859-2866	alanine	abstract[185]|substance[187]|substance	new[185]|new[187]|giv	coref	28-3
26-16	2867-2871	were	_	_	_	_
26-17	2872-2878	highly	_	_	_	_
26-18	2879-2886	related	_	_	_	_
26-19	2887-2889	to	_	_	_	_
26-20	2890-2898	pyruvate	object|abstract[190]	giv|giv[190]	coref|coref|coref|coref	27-1|29-17[207_190]|27-1|29-17[207_190]
26-21	2899-2909	metabolism	abstract[190]	giv[190]	_	_
26-22	2910-2911	.	_	_	_	_

#Text=Pyruvate could be converted to acetyl-coenzyme A ( COA ) , which is a vital intermediate in the synthesis of citrate .
27-1	2912-2920	Pyruvate	substance	giv	coref	28-9
27-2	2921-2926	could	_	_	_	_
27-3	2927-2929	be	_	_	_	_
27-4	2930-2939	converted	_	_	_	_
27-5	2940-2942	to	_	_	_	_
27-6	2943-2958	acetyl-coenzyme	substance	new	appos	27-7[193_0]
27-7	2959-2960	A	substance[193]	giv[193]	_	_
27-8	2961-2962	(	substance[193]	giv[193]	_	_
27-9	2963-2966	COA	substance[193]	giv[193]	_	_
27-10	2967-2968	)	substance[193]	giv[193]	_	_
27-11	2969-2970	,	_	_	_	_
27-12	2971-2976	which	_	_	_	_
27-13	2977-2979	is	_	_	_	_
27-14	2980-2981	a	organization[194]	new[194]	_	_
27-15	2982-2987	vital	organization[194]	new[194]	_	_
27-16	2988-3000	intermediate	organization[194]	new[194]	_	_
27-17	3001-3003	in	organization[194]	new[194]	_	_
27-18	3004-3007	the	organization[194]|abstract[195]	new[194]|new[195]	coref	40-16[270_195]
27-19	3008-3017	synthesis	organization[194]|abstract[195]	new[194]|new[195]	_	_
27-20	3018-3020	of	organization[194]|abstract[195]	new[194]|new[195]	_	_
27-21	3021-3028	citrate	organization[194]|abstract[195]|substance	new[194]|new[195]|giv	_	_
27-22	3029-3030	.	_	_	_	_

#Text=Lactate and alanine can also be converted to pyruvate .
28-1	3031-3038	Lactate	substance|substance[198]	giv|giv[198]	coref|coref|coref|coref	29-3[201_0]|29-3[202_198]|29-3[201_0]|29-3[202_198]
28-2	3039-3042	and	substance[198]	giv[198]	_	_
28-3	3043-3050	alanine	substance[198]|substance	giv[198]|giv	coref	29-7
28-4	3051-3054	can	_	_	_	_
28-5	3055-3059	also	_	_	_	_
28-6	3060-3062	be	_	_	_	_
28-7	3063-3072	converted	_	_	_	_
28-8	3073-3075	to	_	_	_	_
28-9	3076-3084	pyruvate	substance	giv	_	_
28-10	3085-3086	.	_	_	_	_

#Text=Thus , the increased lactate and alanine could promote the level of acetyl-COA and then up-regulate the energy metabolism .
29-1	3087-3091	Thus	_	_	_	_
29-2	3092-3093	,	_	_	_	_
29-3	3094-3097	the	substance[201]|substance[202]	giv[201]|giv[202]	_	_
29-4	3098-3107	increased	substance[201]|substance[202]	giv[201]|giv[202]	_	_
29-5	3108-3115	lactate	substance[201]|substance[202]	giv[201]|giv[202]	_	_
29-6	3116-3119	and	substance[202]	giv[202]	_	_
29-7	3120-3127	alanine	substance[202]|substance	giv[202]|giv	_	_
29-8	3128-3133	could	_	_	_	_
29-9	3134-3141	promote	_	_	_	_
29-10	3142-3145	the	abstract[204]	new[204]	_	_
29-11	3146-3151	level	abstract[204]	new[204]	_	_
29-12	3152-3154	of	abstract[204]	new[204]	_	_
29-13	3155-3165	acetyl-COA	abstract[204]|substance	new[204]|new	_	_
29-14	3166-3169	and	_	_	_	_
29-15	3170-3174	then	_	_	_	_
29-16	3175-3186	up-regulate	_	_	_	_
29-17	3187-3190	the	abstract[207]	giv[207]	coref	30-11[211_207]
29-18	3191-3197	energy	substance|abstract[207]	giv|giv[207]	coref	30-11
29-19	3198-3208	metabolism	abstract[207]	giv[207]	_	_
29-20	3209-3210	.	_	_	_	_

#Text=To sum up , these results indicated the enhancement of energy metabolism in mice after rac -metalaxyl and metalaxyl-M exposure .
30-1	3211-3213	To	_	_	_	_
30-2	3214-3217	sum	_	_	_	_
30-3	3218-3220	up	_	_	_	_
30-4	3221-3222	,	_	_	_	_
30-5	3223-3228	these	abstract[208]	giv[208]	_	_
30-6	3229-3236	results	abstract[208]	giv[208]	_	_
30-7	3237-3246	indicated	_	_	_	_
30-8	3247-3250	the	abstract[209]	new[209]	_	_
30-9	3251-3262	enhancement	abstract[209]	new[209]	_	_
30-10	3263-3265	of	abstract[209]	new[209]	_	_
30-11	3266-3272	energy	abstract[209]|substance|abstract[211]	new[209]|giv|giv[211]	coref|coref|coref|coref	31-15|31-15[223_211]|31-15|31-15[223_211]
30-12	3273-3283	metabolism	abstract[209]|abstract[211]	new[209]|giv[211]	_	_
30-13	3284-3286	in	abstract[209]|abstract[211]	new[209]|giv[211]	_	_
30-14	3287-3291	mice	abstract[209]|abstract[211]|animal	new[209]|giv[211]|giv	_	_
30-15	3292-3297	after	_	_	_	_
30-16	3298-3301	rac	substance|abstract[214]|abstract[215]	giv|giv[214]|giv[215]	coref|coref|coref	31-12|31-12|31-12
30-17	3302-3312	-metalaxyl	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
30-18	3313-3316	and	abstract[215]	giv[215]	_	_
30-19	3317-3328	metalaxyl-M	abstract[215]|abstract[216]	giv[215]|giv[216]	coref	35-10[242_216]
30-20	3329-3337	exposure	abstract[215]|abstract[216]	giv[215]|giv[216]	_	_
30-21	3338-3339	.	_	_	_	_

#Text=Furthermore , the perturbation degrees induced by metalaxy-M were higher than rac -metalaxy in energy metabolism .
31-1	3340-3351	Furthermore	_	_	_	_
31-2	3352-3353	,	_	_	_	_
31-3	3354-3357	the	quantity[218]	new[218]	_	_
31-4	3358-3370	perturbation	abstract|quantity[218]	new|new[218]	_	_
31-5	3371-3378	degrees	quantity[218]	new[218]	_	_
31-6	3379-3386	induced	_	_	_	_
31-7	3387-3389	by	_	_	_	_
31-8	3390-3400	metalaxy-M	substance	new	_	_
31-9	3401-3405	were	_	_	_	_
31-10	3406-3412	higher	_	_	_	_
31-11	3413-3417	than	_	_	_	_
31-12	3418-3421	rac	substance|abstract[221]	giv|new[221]	coref|coref	35-10|35-10
31-13	3422-3431	-metalaxy	abstract[221]	new[221]	_	_
31-14	3432-3434	in	abstract[221]	new[221]	_	_
31-15	3435-3441	energy	abstract[221]|substance|abstract[223]	new[221]|giv|giv[223]	coref|coref	33-1[226_223]|33-1[226_223]
31-16	3442-3452	metabolism	abstract[221]|abstract[223]	new[221]|giv[223]	_	_
31-17	3453-3454	.	_	_	_	_

#Text=3.3 .
32-1	3455-3458	3.3	abstract	new	_	_
32-2	3459-3460	.	_	_	_	_

#Text=Lipid Metabolism
33-1	3461-3466	Lipid	substance|abstract[226]	new|giv[226]	coref|coref|coref|coref	34-8|34-9[0_226]|34-8|34-9[0_226]
33-2	3467-3477	Metabolism	abstract[226]	giv[226]	_	_

#Text=In this study , metalaxyl-M induced two lipid metabolism pathway fluctuations including glycerophospholipid metabolism , glyoxylate , and dicarboxylate metabolism .
34-1	3478-3480	In	_	_	_	_
34-2	3481-3485	this	abstract[227]	new[227]	_	_
34-3	3486-3491	study	abstract[227]	new[227]	_	_
34-4	3492-3493	,	_	_	_	_
34-5	3494-3505	metalaxyl-M	substance	giv	coref	36-6
34-6	3506-3513	induced	_	_	_	_
34-7	3514-3517	two	abstract[232]	new[232]	_	_
34-8	3518-3523	lipid	quantity|abstract[232]	giv|new[232]	coref	35-4
34-9	3524-3534	metabolism	abstract|abstract[232]	giv|new[232]	coref	34-13[234_0]
34-10	3535-3542	pathway	place|abstract[232]	new|new[232]	coref	35-3[240_0]
34-11	3543-3555	fluctuations	abstract[232]	new[232]	_	_
34-12	3556-3565	including	abstract[232]	new[232]	_	_
34-13	3566-3585	glycerophospholipid	abstract[232]|object|abstract[234]	new[232]|new|giv[234]	coref|coref	34-19[237_234]|34-19[237_234]
34-14	3586-3596	metabolism	abstract[232]|abstract[234]	new[232]|giv[234]	_	_
34-15	3597-3598	,	abstract[232]	new[232]	_	_
34-16	3599-3609	glyoxylate	abstract[232]|substance	new[232]|new	_	_
34-17	3610-3611	,	abstract[232]	new[232]	_	_
34-18	3612-3615	and	abstract[232]	new[232]	_	_
34-19	3616-3629	dicarboxylate	abstract[232]|substance|abstract[237]	new[232]|new|giv[237]	coref|coref	35-5[0_237]|35-5[0_237]
34-20	3630-3640	metabolism	abstract[232]|abstract[237]	new[232]|giv[237]	_	_
34-21	3641-3642	.	_	_	_	_

#Text=However , no lipid metabolism pathway was affected by rac -metalaxyl exposure .
35-1	3643-3650	However	_	_	_	_
35-2	3651-3652	,	_	_	_	_
35-3	3653-3655	no	place[240]	giv[240]	_	_
35-4	3656-3661	lipid	abstract|place[240]	giv|giv[240]	coref	39-7
35-5	3662-3672	metabolism	abstract|place[240]	giv|giv[240]	coref	39-7[258_0]
35-6	3673-3680	pathway	place[240]	giv[240]	_	_
35-7	3681-3684	was	_	_	_	_
35-8	3685-3693	affected	_	_	_	_
35-9	3694-3696	by	_	_	_	_
35-10	3697-3700	rac	substance|abstract[242]	giv|giv[242]	_	_
35-11	3701-3711	-metalaxyl	abstract[242]	giv[242]	_	_
35-12	3712-3720	exposure	abstract[242]	giv[242]	_	_
35-13	3721-3722	.	_	_	_	_

#Text=According to metabolomics data , metalaxyl-M induced the increased levels of choline and TMAO and decreased levels of PC and GPC .
36-1	3723-3732	According	_	_	_	_
36-2	3733-3735	to	_	_	_	_
36-3	3736-3748	metabolomics	abstract|abstract[244]	new|new[244]	_	_
36-4	3749-3753	data	abstract[244]	new[244]	_	_
36-5	3754-3755	,	_	_	_	_
36-6	3756-3767	metalaxyl-M	substance	giv	coref	42-14
36-7	3768-3775	induced	_	_	_	_
36-8	3776-3779	the	abstract[246]	new[246]	coref	42-1[285_246]
36-9	3780-3789	increased	abstract[246]	new[246]	_	_
36-10	3790-3796	levels	abstract[246]	new[246]	_	_
36-11	3797-3799	of	abstract[246]	new[246]	_	_
36-12	3800-3807	choline	abstract[246]|substance	new[246]|new	coref	40-1
36-13	3808-3811	and	abstract[246]	new[246]	_	_
36-14	3812-3816	TMAO	abstract[246]|substance	new[246]|new	_	_
36-15	3817-3820	and	abstract[246]	new[246]	_	_
36-16	3821-3830	decreased	abstract[246]|abstract[249]	new[246]|new[249]	_	_
36-17	3831-3837	levels	abstract[246]|abstract[249]	new[246]|new[249]	_	_
36-18	3838-3840	of	abstract[246]|abstract[249]	new[246]|new[249]	_	_
36-19	3841-3843	PC	abstract[246]|abstract[249]|substance|substance[251]	new[246]|new[249]|new|new[251]	coref|coref|coref|coref	42-16|42-16[292_251]|42-16|42-16[292_251]
36-20	3844-3847	and	abstract[246]|abstract[249]|substance[251]	new[246]|new[249]|new[251]	_	_
36-21	3848-3851	GPC	abstract[246]|abstract[249]|substance[251]|substance	new[246]|new[249]|new[251]|new	coref	38-8
36-22	3852-3853	.	_	_	_	_

#Text=Rac
37-1	3854-3857	Rac	abstract	new	_	_

#Text=-metalaxyl only induced the decreased level of GPC .
38-1	3858-3868	-metalaxyl	_	_	_	_
38-2	3869-3873	only	_	_	_	_
38-3	3874-3881	induced	_	_	_	_
38-4	3882-3885	the	abstract[254]	new[254]	coref	39-14[261_254]
38-5	3886-3895	decreased	abstract[254]	new[254]	_	_
38-6	3896-3901	level	abstract[254]	new[254]	_	_
38-7	3902-3904	of	abstract[254]	new[254]	_	_
38-8	3905-3908	GPC	abstract[254]|abstract	new[254]|giv	coref	42-18
38-9	3909-3910	.	_	_	_	_

#Text=Such metabolites were all related to lipid metabolism and had essential effect on cholesterol level in digestive system .
39-1	3911-3915	Such	substance[256]	giv[256]	coref	42-24[294_256]
39-2	3916-3927	metabolites	substance[256]	giv[256]	_	_
39-3	3928-3932	were	_	_	_	_
39-4	3933-3936	all	_	_	_	_
39-5	3937-3944	related	_	_	_	_
39-6	3945-3947	to	_	_	_	_
39-7	3948-3953	lipid	object|abstract[258]	giv|giv[258]	coref|coref|coref|coref	40-10|40-13[268_258]|40-10|40-13[268_258]
39-8	3954-3964	metabolism	abstract[258]	giv[258]	_	_
39-9	3965-3968	and	_	_	_	_
39-10	3969-3972	had	_	_	_	_
39-11	3973-3982	essential	abstract[259]	new[259]	_	_
39-12	3983-3989	effect	abstract[259]	new[259]	_	_
39-13	3990-3992	on	abstract[259]	new[259]	_	_
39-14	3993-4004	cholesterol	abstract[259]|substance|abstract[261]	new[259]|new|giv[261]	_	_
39-15	4005-4010	level	abstract[259]|abstract[261]	new[259]|giv[261]	_	_
39-16	4011-4013	in	abstract[259]|abstract[261]	new[259]|giv[261]	_	_
39-17	4014-4023	digestive	abstract[259]|abstract[261]|organization|abstract[263]	new[259]|giv[261]|new|new[263]	_	_
39-18	4024-4030	system	abstract[259]|abstract[261]|abstract[263]	new[259]|giv[261]|new[263]	_	_
39-19	4031-4032	.	_	_	_	_

#Text=Choline is an important nutrient that is required for lipid transport , methyl-group metabolism , neurotransmitter synthesis , cell membrane structure , and signaling .
40-1	4033-4040	Choline	substance	giv	coref	40-3[265_0]
40-2	4041-4043	is	_	_	_	_
40-3	4044-4046	an	substance[265]	giv[265]	coref	41-4[0_265]
40-4	4047-4056	important	substance[265]	giv[265]	_	_
40-5	4057-4065	nutrient	substance[265]	giv[265]	_	_
40-6	4066-4070	that	_	_	_	_
40-7	4071-4073	is	_	_	_	_
40-8	4074-4082	required	_	_	_	_
40-9	4083-4086	for	_	_	_	_
40-10	4087-4092	lipid	abstract|abstract[267]	giv|new[267]	coref|coref	41-27|41-27
40-11	4093-4102	transport	abstract[267]	new[267]	_	_
40-12	4103-4104	,	_	_	_	_
40-13	4105-4117	methyl-group	abstract[268]	giv[268]	coref	41-27[283_268]
40-14	4118-4128	metabolism	abstract[268]	giv[268]	_	_
40-15	4129-4130	,	_	_	_	_
40-16	4131-4147	neurotransmitter	abstract|abstract[270]	new|giv[270]	_	_
40-17	4148-4157	synthesis	abstract[270]	giv[270]	_	_
40-18	4158-4159	,	_	_	_	_
40-19	4160-4164	cell	abstract[272]	new[272]	_	_
40-20	4165-4173	membrane	object|abstract[272]	new|new[272]	coref	41-24[281_0]
40-21	4174-4183	structure	abstract[272]	new[272]	_	_
40-22	4184-4185	,	_	_	_	_
40-23	4186-4189	and	_	_	_	_
40-24	4190-4199	signaling	abstract	new	_	_
40-25	4200-4201	.	_	_	_	_

#Text=In addition , choline is a constituent of cell membranes and lipoprotein phospholipids , which play an important role in the integrity of cell membrane and lipid metabolism .
41-1	4202-4204	In	_	_	_	_
41-2	4205-4213	addition	_	_	_	_
41-3	4214-4215	,	_	_	_	_
41-4	4216-4223	choline	substance	giv	coref	41-6[275_0]
41-5	4224-4226	is	_	_	_	_
41-6	4227-4228	a	substance[275]	giv[275]	coref	42-2[0_275]
41-7	4229-4240	constituent	substance[275]	giv[275]	_	_
41-8	4241-4243	of	substance[275]	giv[275]	_	_
41-9	4244-4248	cell	substance[275]|object[276]	giv[275]|new[276]	coref	43-13[304_276]
41-10	4249-4258	membranes	substance[275]|object[276]	giv[275]|new[276]	_	_
41-11	4259-4262	and	substance[275]	giv[275]	_	_
41-12	4263-4274	lipoprotein	substance[275]|substance|object[278]	giv[275]|new|new[278]	_	_
41-13	4275-4288	phospholipids	substance[275]|object[278]	giv[275]|new[278]	_	_
41-14	4289-4290	,	_	_	_	_
41-15	4291-4296	which	_	_	_	_
41-16	4297-4301	play	_	_	_	_
41-17	4302-4304	an	abstract[279]	new[279]	_	_
41-18	4305-4314	important	abstract[279]	new[279]	_	_
41-19	4315-4319	role	abstract[279]	new[279]	_	_
41-20	4320-4322	in	abstract[279]	new[279]	_	_
41-21	4323-4326	the	abstract[279]|abstract[280]	new[279]|new[280]	_	_
41-22	4327-4336	integrity	abstract[279]|abstract[280]	new[279]|new[280]	_	_
41-23	4337-4339	of	abstract[279]|abstract[280]	new[279]|new[280]	_	_
41-24	4340-4344	cell	abstract[279]|abstract[280]|object[281]	new[279]|new[280]|giv[281]	coref	42-9[0_281]
41-25	4345-4353	membrane	abstract[279]|abstract[280]|object[281]	new[279]|new[280]|giv[281]	_	_
41-26	4354-4357	and	abstract[279]|abstract[280]	new[279]|new[280]	_	_
41-27	4358-4363	lipid	abstract[279]|abstract[280]|object|abstract[283]	new[279]|new[280]|giv|giv[283]	_	_
41-28	4364-4374	metabolism	abstract[279]|abstract[280]|abstract[283]	new[279]|new[280]|giv[283]	_	_
41-29	4375-4376	.	_	_	_	_

#Text=Increased choline levels in urine samples suggested the membrane fluidity was disrupted by metalaxyl-M . PC and GPC are known to be important endogenous metabolites related to maintenance of choline homeostasis and bile acids excretion .
42-1	4377-4386	Increased	abstract[285]	giv[285]	_	_
42-2	4387-4394	choline	abstract|abstract[285]	giv|giv[285]	coref	42-30
42-3	4395-4401	levels	abstract[285]	giv[285]	_	_
42-4	4402-4404	in	abstract[285]	giv[285]	_	_
42-5	4405-4410	urine	abstract[285]|substance|object[287]	giv[285]|giv|new[287]	_	_
42-6	4411-4418	samples	abstract[285]|object[287]	giv[285]|new[287]	_	_
42-7	4419-4428	suggested	_	_	_	_
42-8	4429-4432	the	substance[289]	new[289]	_	_
42-9	4433-4441	membrane	object|substance[289]	giv|new[289]	_	_
42-10	4442-4450	fluidity	substance[289]	new[289]	_	_
42-11	4451-4454	was	_	_	_	_
42-12	4455-4464	disrupted	_	_	_	_
42-13	4465-4467	by	_	_	_	_
42-14	4468-4479	metalaxyl-M	substance	giv	coref	44-19
42-15	4480-4481	.	_	_	_	_
42-16	4482-4484	PC	object|substance[292]	giv|giv[292]	coref|coref|coref|coref	43-3|43-3[301_292]|43-3|43-3[301_292]
42-17	4485-4488	and	substance[292]	giv[292]	_	_
42-18	4489-4492	GPC	substance[292]|substance	giv[292]|giv	coref	43-6
42-19	4493-4496	are	_	_	_	_
42-20	4497-4502	known	_	_	_	_
42-21	4503-4505	to	_	_	_	_
42-22	4506-4508	be	_	_	_	_
42-23	4509-4518	important	_	_	_	_
42-24	4519-4529	endogenous	substance[294]	giv[294]	_	_
42-25	4530-4541	metabolites	substance[294]	giv[294]	_	_
42-26	4542-4549	related	_	_	_	_
42-27	4550-4552	to	_	_	_	_
42-28	4553-4564	maintenance	abstract[295]	new[295]	_	_
42-29	4565-4567	of	abstract[295]	new[295]	_	_
42-30	4568-4575	choline	abstract[295]|abstract|abstract[297]	new[295]|giv|new[297]	_	_
42-31	4576-4587	homeostasis	abstract[295]|abstract[297]	new[295]|new[297]	_	_
42-32	4588-4591	and	abstract[295]	new[295]	_	_
42-33	4592-4596	bile	abstract[295]|abstract[299]	new[295]|new[299]	_	_
42-34	4597-4602	acids	abstract[295]|substance|abstract[299]	new[295]|new|new[299]	_	_
42-35	4603-4612	excretion	abstract[295]|abstract[299]	new[295]|new[299]	_	_
42-36	4613-4614	.	_	_	_	_

#Text=Moreover , PC , and GPC are not only essential components of cell membranes , but also protect cell from oxidative stress and lipotoxicity .
43-1	4615-4623	Moreover	_	_	_	_
43-2	4624-4625	,	_	_	_	_
43-3	4626-4628	PC	object|substance[301]	giv|giv[301]	coref|coref|coref|coref	44-5|44-5[311_301]|44-5|44-5[311_301]
43-4	4629-4630	,	substance[301]	giv[301]	_	_
43-5	4631-4634	and	substance[301]	giv[301]	_	_
43-6	4635-4638	GPC	substance[301]|substance	giv[301]|giv	coref	44-7
43-7	4639-4642	are	_	_	_	_
43-8	4643-4646	not	_	_	_	_
43-9	4647-4651	only	abstract[303]	new[303]	_	_
43-10	4652-4661	essential	abstract[303]	new[303]	_	_
43-11	4662-4672	components	abstract[303]	new[303]	_	_
43-12	4673-4675	of	abstract[303]	new[303]	_	_
43-13	4676-4680	cell	abstract[303]|object[304]	new[303]|giv[304]	_	_
43-14	4681-4690	membranes	abstract[303]|object[304]	new[303]|giv[304]	_	_
43-15	4691-4692	,	_	_	_	_
43-16	4693-4696	but	_	_	_	_
43-17	4697-4701	also	_	_	_	_
43-18	4702-4709	protect	_	_	_	_
43-19	4710-4714	cell	place	new	_	_
43-20	4715-4719	from	_	_	_	_
43-21	4720-4729	oxidative	abstract|abstract[307]	new|new[307]	coref|coref|coref|coref	44-13|44-13[315_307]|44-13|44-13[315_307]
43-22	4730-4736	stress	abstract[307]	new[307]	_	_
43-23	4737-4740	and	_	_	_	_
43-24	4741-4753	lipotoxicity	substance	new	coref	44-16
43-25	4754-4755	.	_	_	_	_

#Text=The decreased levels of PC and GPC may be good indicators of oxidative stress and lipotoxicity induced by metalaxyl-M .
44-1	4756-4759	The	abstract[309]	new[309]	coref	44-10[313_309]
44-2	4760-4769	decreased	abstract[309]	new[309]	_	_
44-3	4770-4776	levels	abstract[309]	new[309]	_	_
44-4	4777-4779	of	abstract[309]	new[309]	_	_
44-5	4780-4782	PC	abstract[309]|substance|substance[311]	new[309]|giv|giv[311]	_	_
44-6	4783-4786	and	abstract[309]|substance[311]	new[309]|giv[311]	_	_
44-7	4787-4790	GPC	abstract[309]|substance[311]|substance	new[309]|giv[311]|giv	_	_
44-8	4791-4794	may	_	_	_	_
44-9	4795-4797	be	_	_	_	_
44-10	4798-4802	good	abstract[313]	giv[313]	_	_
44-11	4803-4813	indicators	abstract[313]	giv[313]	_	_
44-12	4814-4816	of	abstract[313]	giv[313]	_	_
44-13	4817-4826	oxidative	abstract[313]|abstract|abstract[315]	giv[313]|giv|giv[315]	_	_
44-14	4827-4833	stress	abstract[313]|abstract[315]	giv[313]|giv[315]	_	_
44-15	4834-4837	and	abstract[313]	giv[313]	_	_
44-16	4838-4850	lipotoxicity	abstract[313]|substance	giv[313]|giv	_	_
44-17	4851-4858	induced	_	_	_	_
44-18	4859-4861	by	_	_	_	_
44-19	4862-4873	metalaxyl-M	substance	giv	_	_
44-20	4874-4875	.	_	_	_	_
